| Primary |
| Product Used For Unknown Indication |
20.5% |
| Bone Marrow Conditioning Regimen |
12.1% |
| Infection Prophylaxis |
10.1% |
| Prophylaxis |
9.9% |
| Aplastic Anaemia |
8.4% |
| Prophylaxis Against Graft Versus Host Disease |
7.3% |
| Premedication |
5.9% |
| Prophylaxis Against Transplant Rejection |
3.7% |
| Antifungal Prophylaxis |
3.7% |
| Immunosuppression |
2.7% |
| Renal Transplant |
2.7% |
| Antiviral Prophylaxis |
2.1% |
| Acute Myeloid Leukaemia |
2.1% |
| Antibiotic Prophylaxis |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Acute Graft Versus Host Disease |
1.3% |
| Graft Versus Host Disease |
1.0% |
| Prophylaxis Of Nausea And Vomiting |
1.0% |
| Hypertension |
0.8% |
|
| Pyrexia |
14.3% |
| Serum Sickness |
8.8% |
| Transplant Rejection |
8.2% |
| White Blood Cell Count Decreased |
5.8% |
| Sepsis |
5.4% |
| Thrombotic Microangiopathy |
5.4% |
| Death |
4.9% |
| Thrombocytopenia |
4.9% |
| Febrile Neutropenia |
4.8% |
| Multi-organ Failure |
4.0% |
| Renal Failure |
3.9% |
| Vomiting |
3.8% |
| Staphylococcal Sepsis |
3.7% |
| Tachycardia |
3.5% |
| Therapeutic Response Decreased |
3.5% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.3% |
| Kidney Transplant Rejection |
3.1% |
| Liver Transplant Rejection |
3.0% |
| Graft Versus Host Disease |
2.9% |
| Pulmonary Oedema |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
21.2% |
| Bone Marrow Conditioning Regimen |
10.6% |
| Infection Prophylaxis |
9.9% |
| Prophylaxis Against Graft Versus Host Disease |
9.2% |
| Prophylaxis |
5.8% |
| Stem Cell Transplant |
5.1% |
| Renal Transplant |
5.0% |
| Premedication |
4.9% |
| Acute Myeloid Leukaemia |
3.5% |
| Aplastic Anaemia |
3.4% |
| Drug Use For Unknown Indication |
3.2% |
| Antifungal Prophylaxis |
3.0% |
| Immunosuppression |
2.8% |
| Prophylaxis Against Transplant Rejection |
2.8% |
| Acute Graft Versus Host Disease |
2.2% |
| Myelodysplastic Syndrome |
2.0% |
| Antiviral Prophylaxis |
1.7% |
| Antibiotic Prophylaxis |
1.5% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Graft Versus Host Disease |
1.0% |
|
| Pyrexia |
15.4% |
| Acute Graft Versus Host Disease |
10.4% |
| White Blood Cell Count Decreased |
7.2% |
| Serum Sickness |
5.8% |
| Transplant Rejection |
5.5% |
| Death |
5.4% |
| Thrombocytopenia |
5.4% |
| Thrombotic Microangiopathy |
4.6% |
| Rash |
4.5% |
| Venoocclusive Disease |
4.3% |
| Transplant Failure |
4.2% |
| Sepsis |
3.7% |
| Multi-organ Failure |
3.4% |
| Graft Versus Host Disease |
3.3% |
| Tachycardia |
3.1% |
| Acute Graft Versus Host Disease In Skin |
3.0% |
| Chronic Graft Versus Host Disease |
2.8% |
| Myelodysplastic Syndrome |
2.7% |
| Septic Shock |
2.7% |
| Therapeutic Response Decreased |
2.7% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
14.3% |
| Product Used For Unknown Indication |
12.2% |
| Renal Transplant |
9.8% |
| Surgical Preconditioning |
8.9% |
| Stem Cell Transplant |
7.8% |
| Premedication |
6.1% |
| Antifungal Prophylaxis |
5.7% |
| Prophylaxis |
5.2% |
| Immunosuppression |
4.8% |
| Drug Use For Unknown Indication |
4.5% |
| Infection Prophylaxis |
3.6% |
| Antibiotic Prophylaxis |
3.0% |
| Anaemia Prophylaxis |
2.9% |
| Prophylaxis Against Transplant Rejection |
2.6% |
| Bone Marrow Conditioning Regimen |
2.5% |
| Acute Myeloid Leukaemia |
1.4% |
| Cord Blood Transplant Therapy |
1.3% |
| Haematopoietic Stem Cell Mobilisation |
1.3% |
| Immunosuppressant Drug Therapy |
1.1% |
| Hypertension |
0.9% |
|
| Transplant Rejection |
16.5% |
| Graft Versus Host Disease |
11.5% |
| Stem Cell Transplant |
11.0% |
| Venoocclusive Disease |
6.6% |
| Thrombotic Microangiopathy |
6.0% |
| White Blood Cell Count Decreased |
4.9% |
| Sepsis |
4.4% |
| Vomiting |
4.4% |
| Cardiac Arrest |
3.8% |
| Staphylococcal Infection |
3.8% |
| Multi-organ Failure |
3.3% |
| Therapeutic Response Decreased |
3.3% |
| Bone Marrow Failure |
2.7% |
| Proteinuria |
2.7% |
| Skin Tightness |
2.7% |
| Thrombocytopenia |
2.7% |
| Weight Decreased |
2.7% |
| Acute Respiratory Distress Syndrome |
2.2% |
| Aplasia Pure Red Cell |
2.2% |
| Atrial Fibrillation |
2.2% |
|
| Interacting |
| Drug Use For Unknown Indication |
100.0% |
|
| Operative Haemorrhage |
100.0% |
|
